

# Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS)

Fadia Dib, Yann de Rycke, Sylvie Guillo, Alexandre Lafourcade, Chantal

Raherison, Camille Taillé, Florence Tubach

## ▶ To cite this version:

Fadia Dib, Yann de Rycke, Sylvie Guillo, Alexandre Lafourcade, Chantal Raherison, et al.. Impact of a population-based asthma management program in France (Sophia Asthme): A matched controlled before-and-after quasi-experimental study using the French health insurance database (SNDS). Pharmacoepidemiology and Drug Safety, 2019, 28 (8), pp.1097-1108. 10.1002/pds.4842 . hal-02289350

## HAL Id: hal-02289350 https://hal.sorbonne-universite.fr/hal-02289350

Submitted on 16 Sep 2019  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## 1 TITLE PAGE

- Impact of a population-based asthma management program in France 2 (Sophia Asthme): a matched controlled before-and-after quasi experimental 3 study using the French health insurance database (SNDS) 4 5 6 Fadia Dib \*1,2,3 MD, Yann de Rycke Y\*4 MSc, Sylvie Guillo <sup>4</sup> MSc, Alexandre Lafourcade <sup>4</sup> MSc, 7 Chantal Raherison <sup>5,6</sup> MD-PhD, Camille Taillé C <sup>7</sup> MD-PhD, Florence Tubach <sup>4</sup> MD-PhD. 8 9 10 \*contributed equally 11 12 <sup>1</sup> AP-HP, Hôpital Bichat-Claude-Bernard, Département d'Epidémiologie, Biostatistiques et 13 Recherche Clinique, F- 75018 Paris, France <sup>2</sup> INSERM, CIC-EC 1425, 75018, Paris, France 14 15 <sup>3</sup> Université Paris Diderot, Sorbonne Paris Cité, ECEVE, UMRS 1123, F-75010 Paris, France <sup>4</sup>Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique, 16 IPLESP UMR-S1136, CIC 1421, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique 17 18 Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie, Céphépi, F-19 75013 Paris, France <sup>5</sup> INSERM U1219 team EPICENE, Bordeaux University 146 rue Leo Saignat 33076 Bordeaux 20 21 France 22 <sup>6</sup> Service des Maladies Respiratoires, CHU Bordeaux, Place Amélie Raba Léon, 33000 23 Bordeaux 24 <sup>7</sup> Service de Pneumologie et Centre de Compétence des Maladies Pulmonaires Rares, Hôpital 25 Bichat, AP-HP, Paris et Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France 26 27 28 29 Corresponding author: Pr Florence Tubach, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie, 30 Céphépi, Unité de recherche clinique, INSERM, UMR 1123, CIC-P 1421, F-75013 Paris, France. 31 E-mail: florence.tubach@aphp.fr. Tel: 01.42.16.05.88 32 33 34 Key words: Asthma control, Asthma exacerbation, Asthma outcomes, Disease management 35 program
- 36

37 ABSTRACT

38

Background: Sophia Asthme (SA) is a chronic disease management program of the French
national health insurance for adult patients with asthma. We evaluated the early impact of
this intervention.

42 **Methods:** We conducted a matched controlled, before-and-after quasi-experimental study 43 within the French Health Insurance Database (SNDS). The SA program was implemented in a 44 set of 18 Départements in France and targeted 18-to 44-year-old subjects, with at least two 45 reimbursement dates for asthma drug therapy during the 12-month period prior to program 46 targeting. Change in outcomes was assessed from the "before program" period (January-47 December 2014) to the "after program implementation" period (Mars 2015–February 2016) in the program group (eligible to SA program in the 18 Départements) and in the matched 48 49 controlled group. The main outcome measure was the before-after change in proportion of subjects with a controllers/(controllers+relievers) ratio >50%. 50

**Findings:** Of the 99,578 subjects of the program group, 9,225 (9·3%) actually participated in SA program. The program had no significant impact on the proportion of subjects with a ratio>50%. However, subjects exposed to SA program were significantly more likely to be dispensed controller medications (OR=1·04; 95% Cl, 1·01 to 1·07), and to sustain their use of these medications (OR = 1·08; 95% Cl, 1·05 to 1·12).

Interpretation: We did not demonstrate any significant impact of the program on the primary outcome. The modest yet encouraging findings of this early evaluation suggest the need for reformulation of the program and its evaluation.

- 59 **Funding:** Caisse Nationale d'Assurance Maladie, Paris, France.
- 60

#### 61 **INTRODUCTION**

Despite the availability of highly effective therapies, achieving asthma control remains tremendously challenging, mostly because of inappropriate use of asthma controller medications. <sup>1</sup> Poor asthma control is responsible for acute exacerbations, which can lead to emergency visits, hospitalizations, and even premature deaths. With an estimated global asthma prevalence among adults ranging from 1% to 21% <sup>2</sup> and 383,000 related deaths in 2015, <sup>3</sup> asthma places substantial burdens on the patients, healthcare system and society; <sup>4,5</sup> it is a major public health problem recognized by the World Health Organization (WHO).<sup>3</sup>

69 Various programs have been implemented worldwide to improve asthma control.<sup>6</sup> Sophia

Asthme (SA) program is a chronic disease management program developed by the National
 French Insurance Service (*Caisse Nationale de l'Assurance Maladie* (CNAM)). It aims to
 enhance self-management and induce behavior changes, at a sustainable cost to the CNAM
 budget.

Sophia program was first developed for diabetic patients in 2008, and included a free web site, written information and telephonic nurse intervention. Recently, a pilot program was developed for asthma patients, aiming at improving asthma control. The objective of this study commissioned by the CNAM was to assess the early effect of the pilot phase of the SA program on asthma outcomes in adult asthma patients.

#### 80 METHODS

#### 81 **Description of the intervention**

82

As a health insurer, the CNAM defines and implements risk-management actions. In this 83 framework, the CNAM launched the pilot experiment of SA program <sup>7</sup> in January 2015, in 18 84 among 96 Départements of mainland France (Alpes-Maritimes, Ariège, Côte-d'Or, Haute-85 Garonne, Gers, Gironde, Hérault, Loire, Loiret, Marne, Meurthe-et-Moselle, Nord, Puy-de-86 Dôme, Hautes-Pyrénées, Sarthe, Somme, Tarn, and Seine-Saint-Denis). Targeting the 18- to 87 44-year-old asthmatic patients, SA program consists primarily of a nurse-delivered, phone-88 based intervention. Every individual identified in the CNAM claims databases and meeting 89 90 the selection criteria was invited to take part in the program. The program participants (as 91 opposed to "program non-participants") started receiving phone calls after mail or online registration made by the patient or their general practitioner (GP). 92

During the first phone call, medical data (asthma control during the last 4 weeks according 93 to Global Initiative for Asthma (GINA) criteria<sup>8</sup>, smoking status and physical exercise practice) 94 were collected. During the following calls, specialized nurses trained in behavioral counseling 95 96 conducted motivational interviews to promote positive attitudes towards asthma, using a 97 computer-assisted telephone system. Telephone calling periodicity was determined initially and updated afterwards according to a set of criteria reflecting asthma control. After the 98 99 first phone call, a bimonthly call was planned for patients who had had a hospitalization or 100 ER visit for asthma and for those who had poor symptom control according to GINA criteria. An annual call was planned otherwise. Hospitalization and ER visits for asthma were 101 monitored in real-time (from claims/hospital discharge data) for all program participants, so 102 103 that patients could benefit from additional calls in the event where asthma hospitalization or

104 ER visit occurred since the last phone call. The same criteria were applied after the second call to determine the periodicity of the subsequent calls. These criteria encompassed both 105 106 asthma control and medical use from the SNDS database. The content of counseling was recorded in a dedicated software, and tailored for each program participant based on its 107 personal situation (lifestyle, state of health and medical care, social and family 108 109 environment). Nurses offered appropriate advice and information, in order to promote a greater understanding of the relation between medication adherence and asthma control. 110 111 They urged patients to seek medical aid and drug treatment, when appropriate.

Participants without any telephone call during the intervention period were classified as participants with "low–intensity intervention", those who had one to three and more than three calls as participants with "moderate-intensity and "high-intensity intervention", respectively.

Besides telephone calls, all program participants received printed material developed by health care professionals and validated by a scientific committee. The material included three leaflets and bi-monthly e-newsletters on asthma. The CNAM also provided unrestricted access to a dedicated website. The written material and the website included information on prevention of exacerbations, smoking cessation, physical activity and management of the disease.

#### 122 Population

Subjects for the pilot experiment were identified and followed-up within the French Health Insurance database (*Système National Des Données de Santé- SNDS*). Eligibility criteria for the SA program were the following: 1) being aged 18 to 44 years; 2) having at least two different reimbursement dates for asthma medications (RO3 codes according to the

Anatomical Therapeutic and Chemical (ATC) classification system) in the last 12 months; 3) being covered by the general health insurance scheme; 4) being affiliated with a local healthcare insurance office (*Caisse Primaire d'Assurance Maladie* – CPAM) attached to any of the 18 aforementioned *Départements* for at least 12 months before program deployment; and 5) having a GP also affiliated with a CPAM attached to any of the 18 aforementioned *Départements* for at least 12 months before program deployment.

The study population involved all subjects eligible to SA program from *Départements* with the program (i.e., the exposed) matched on a propensity score and stratification variables, with subjects eligible to SA program except they and their GP were affiliated with a CPAM of mainland *Départements* not covered by the program (i.e., the unexposed).

The geographical areas chosen for the pilot experiment cover a population of approximately
168,000 subjects meeting the aforementioned eligibility criteria. This population was not
chosen to be strictly representative of all asthmatic patients in France.

#### 140 Study design

This evaluation study was designed as a prospective, non-randomized, matched controlled, 141 quasi-experimental before-and-after study.<sup>9</sup> We defined three periods: (i) 1 January 2014 – 142 143 31 December 2014: the 12-month "before program implementation" period, (ii) 1 January 2015 – 28 February 2015: the implementation period, and (iii) 1 March 2015 – 29 February 144 2016: the 12-month "after program implementation" period. The exposed group 145 146 (intervention group) was composed of individuals targeted by SA program. The unexposed group was composed of matched individuals meeting eligibility criteria of the intervention 147 group except they and their GP were affiliated with CPAM of mainland Départements not 148 149 covered by the program. Each subject from the intervention group was matched with an unexposed, by stratification variables (asthma-related hospital stay in the last 12 months (yes vs. no), the number of asthma drug deliveries in the last 12 months (2 vs.  $\geq$ 3) and age at program enrollment (< 40 vs.  $\geq$  40)), and by the propensity score of being exposed.<sup>10–12</sup> We report our findings in accordance with The Reporting Quality of Non Randomized Evaluations of Behavioral and Public Health Interventions (TREND) statement. <sup>13</sup>

#### 155 Outcome measures

The outcomes were extracted from the SNDS database in 2015 and match the desired effects of the intervention: improved asthma control, improved adherence to controller asthma medications, improved use of healthcare resources, reduced exacerbations and days off work.

160 The primary outcome of interest relied on an asthma medication ratio measuring the proportion of controllers out of total asthma therapy (i.e., controllers and relievers) over a 161 given study period. <sup>14</sup> More precisely, it is the ratio of inhaled corticosteroid (ICS) (whether in 162 fixed combination with long-acting β-agonists (LABAs) or not) plus leukotriene receptor 163 164 antagonist (LTRA) to total asthma medications (R03 according to ATC classification, Appendix 165 1). In this study, the primary outcome was a high ICS+LTRA/R03 ratio (i.e.,  $\geq$  50%), which has 166 been shown in claims data to be associated with fewer asthma-related hospitalizations, fewer emergency room (ER) visits,<sup>14</sup> and better patient-centered asthma outcomes (such as 167 asthma quality of life and symptoms severity).<sup>15</sup> The secondary outcomes included asthma 168 exacerbations (defined as asthma-related hospitalization, asthma -related ER visit or visit to 169 170 the GP with a dispensation of systemic corticosteroids within seven days of the GP visit), 171 urgent care visits (asthma-related ER room visits and hospitalizations, GP visits for asthma 172 exacerbations), routine asthma visits (GP visits for asthma- defined as dispensation of R03 173 drugs within seven days of the GP visit-, pulmonologist visits, and pulmonary function

testing), dispensation of at least one controller medication, dispensation of four or more
SABA, sustained use of controller medications (defined as five or more dispensations of ICS in fixed association with LABA or not- or eight or more units of LTRA), adherence to asthma
controller medication (ICS alone or in fixed combination with LABA) as measured by the
Medication Refill Adherence (MRA), <sup>16</sup> and work absenteeism as measured by the number of
sick leave days related to asthma (Appendix 2).

#### 180 Data sources

181 This study was undertaken using a database formed by linking the SNDS <sup>17</sup> database and SA 182 program database, which only included the program participants (questionnaire 183 administered upon entry into the study, and program operational data).

In France, the SNDS compiles data from the French National Health Insurance System 184 (including the national hospital-discharge summaries database system - PMSI).<sup>18</sup> Information 185 on healthcare reimbursement, ambulatory and hospital expenditures data, as well as socio-186 demographics including age, gender, French administrative area of residence, advantage of 187 188 the Complementary Universal Health Coverage (CMU-C, an individual measure of low socioeconomic position (SEP)), and long-term chronic disease status allowing for full medical 189 190 reimbursement, is available in the SNDS. Data obtained for subjects included in our study comprise sociodemographic and outpatient reimbursed health visits and drugs (coded with 191 192 ATC classification) on the one hand, and the dates of start and end of hospital stays, with related and associated diagnoses coded with the 193 diagnostic codes (primary, International Information Classification of Diseases, version ICD-10), <sup>19</sup> and most of costly 194 procedures (Classification commune des actes médicaux, CCAM),<sup>20</sup> on the other hand. The 195 196 study funder and commissioner (National Health Insurance Fund) undertook the linkage 197 between SNDS records and the information collected within SA program. According to the 198 law (n°2016-41, JORF 2016), a permanent access to SNDS is granted to CNAM employees, but also to subcontractor acting under the authority of CNAM, under very strict conditions 199 (accreditations, secure access...). The statistician authors, as subcontractors to CNAM, had 200 complete and free access to the database. This evaluation is covered by the law of the 6th 201 January 1978 and the decree n ° 2012-1249 of the 9th November 2012 authorizing the 202 203 creation of personal data processing for the implementation of health prevention and support programs for insured persons. The data processing was the subject of a 204 commitment of conformity to the aforementioned decree. 205

#### 206 **Power calculation**

The a priori power calculation was based on a 5 % increase in the proportion of patients with a ratio ICS+LTRA/R03  $\geq$  50% among program participants and their matched unexposed subjects in the intervention group. Assuming 160,000 subjects in the exposed group and a rate of 10% of program participation, we reached a power of 80% with a 5% two-tailed test.

#### 211 Statistical methods

We generated a propensity score with all the subjects, for matching subjects of the 212 intervention (exposed) and unexposed groups within each stratum (caliper=0.20). The 213 214 probability of being exposed to the program was modeled using a multivariate logistic regression including the following covariates: age, sex, average number of units of the ATC 215 216 R03 class delivered over the years 2012, 2013 and 2014, CMU-C, prevalence of asthma in the 217 area of residence, as well as characteristics of the geographic location of GP practice (Rey 218 deprivation index, <sup>21</sup> which is an area-level measure of SEP, the medical density, the size, and the rural or urban character). <sup>22</sup> The prevalence of asthma reflects in an integrated and 219 220 pragmatic way the factors that trigger asthma exacerbations (such as atmospheric

221 conditions, weather conditions, pollination, influenza, etc.); it was derived from a national survey of adults in France (Enquête santé protection sociale -ESPS)<sup>23</sup> and a national school 222 health survey.<sup>24,25</sup> We used standardized mean differences and histograms, for analyzing 223 balance in measured baseline variables before and after matching. After propensity-score 224 matching, we compared differences in patient's outcomes using the difference-in-225 226 differences (DiD) analysis approach. We compared the change in outcomes in subjects of the intervention group between the "before program implementation" period and the "after 227 228 program implementation" period with the change of outcomes in subjects of the unexposed group within the same time period, by use of linear mixed models and generalized mixed 229 models for testing the effect of the program on continuous and dichotomous outcomes, 230 respectively. 231

We conducted subgroup analyses to focus on populations in which the probability to be asthmatic was higher than in the whole study population: (i) patients with at least three different reimbursement dates of R03 in 2013 (*a priori* subgroup analysis), (ii) patients with at least one reimbursement date of R03 in 2012, and (iii) patients with more stringent criteria for the definition of asthma (algorithm developed by the CNAM: subjects with  $\geq$  1 IgE antagonist or  $\geq$  1 xanthine or  $\geq$  1 LTRA (alone or with ICS) or  $\geq$  3 ICS-LABA or  $\geq$  3 ICS or  $\geq$  3 LABA or  $\geq$  3 SABA are considered asthmatic).

All analyses were conducted using SAS guide 9.3 (SAS Institute, Cary NC) and R version 3.1.1. R Core Team (2014).<sup>26</sup> A level of a two-tailed statistical significance of p < 0.05 was used for all statistical tests performed. 242 **RESULTS** 

#### 243 Baseline characteristics

In January 2015, 108,053 subjects were targeted by SA program. Of those, 105,957 were 244 eligible to the intervention group of the study (Figure 1). After matching, 199,156 individuals 245 were included in the study, with 99,578 in each group. The quality of propensity matching is 246 247 graphically displayed in Supplemental Figures S1A and S1B (Appendix 3). Mean age (± SD) was 34 (±7) years (IQR 29-41). Women and CMU-C recipients constituted respectively 60.3% 248 249 and 19.5% of the study population (Table 1). This population was characterized by features suggesting poor asthma control (less than half of them had an ICS+LTRA/R03 drug ratio  $\geq 0.5$ , 250 one third of them exhibited at least one asthma exacerbation during the previous year) and 251 252 little adherence to treatment (7.1% had a MRA >80%)) (Table 2). A small proportion (11%) of 253 them consulted a lung specialist and about a half received ICS (alone or in combination with LABA) during the year preceding the program. 254

#### 255 Description of Sophia Asthme program outputs

In the intervention group, 9,225 (9·3%) subjects actually participated in the program. Mean number telephone calls was 1·8. Fifty-four percent of the participants had "low-intensity intervention"; 30·4 % and 15·6 % had "moderate-intensity" and "high-intensity intervention", respectively.

The written support provided was the same for all participants, but only those who communicated their e-mail address (58·8%) received the e-newsletters. Among them, the majority received four or five e-newsletters (18·9 % and 31·8 % of the participants, respectively). The majority of the participants (80·6%) received three leaflets; 16·2 % received two leaflets.

#### 265 Effects of Sophia Asthme program

Table 2 presents the evolution of outcomes before and after program implementation. Most 266 indicators decreased over time in both the intervention and the unexposed group, indicating 267 268 a period effect. From the "before program implementation" period to the "after program implementation" period, the proportion of subjects with a high ICS+LTRA/R03 decreased in 269 both groups by 4.9 %. No significant difference was observed for other asthma control or for 270 271 medication adherence indicators. However, the effect of SA program was significant in terms of more frequent patients with at least one controller medication prescription dispensed (OR 272 = 1.04; 95% CI, 1.01 to 1.07), with sustained use of controller medications (OR = 1.08; 95% CI, 273 274 1.05 to 1.12), and with higher total number of R03 prescriptions dispensed ( $\beta$  = 0.36; 95% Cl, 0.25 to 0.47) in the intervention group.. 275

#### 276 Subgroup analyses

277 The results were similar for patients with three or more R03 prescriptions dispensed in the 278 last 12 months prior to program targeting (in 2013), but the program effect size was relatively larger on the total number of R03 prescriptions dispensed ( $\beta$  = 0.51; 95% CI, 0.35 279 280 to 0.67). The comparison of program participants to their matched unexposed showed larger 281 effects sizes on the sustained use of controller medications (OR = 1.29; 95% CI, 1.16 to 1.43) 282 and on the total number of R03 prescriptions dispensed ( $\beta = 0.76$ ; 95% CI, 0.36to 1.16). In addition, this subgroup analysis revealed a significant protective effect of the program on 283 284 the risk of asthma exacerbations (OR = 0.90; 95% CI, 0.83to 0.99) and a significant decrease 285 in the number of asthma-related sickleave days ( $\beta = -0.33$ ; 95% Cl, -0.59 to -0.07) (Table 2). 286 Results were similar in the people with asthma according to the CNAM algorithm (Table 3).

287 **DISCUSSION** 

In this paper, we have examined the early impact of an asthma disease management 288 program in France, SA. The study did not achieve its primary objective, which was to 289 290 demonstrate an increase in the proportion of patients with a high ICS+LTRA/R03 ratio in the intervention group. Additionally, there was no evidence that the program reduced the risk of 291 asthma-related hospitalizations, ER visits for acute asthma, and asthma exacerbations. 292 293 However, the program was found to be associated with an increase in the dispensation of 294 R03, the proportion of subjects with dispensation of at least one controller medication, and 295 the sustained use of controller medications. Furthermore, in subgroup analyses focusing on 296 people more likely to be asthmatic, the impact of the program was significant for some asthma treatment-related outcomes (R03 prescriptions dispensed, at least one controller 297 medication prescription dispensed, sustained use of controller medications), and some 298 299 clinical outcomes (asthma exacerbations, number of asthma-related sickleave days).

300 These results can be interpreted as an absence of impact of the SA program. However, 301 alternative explanations must be discussed. First, the (two months') duration of the implementation period was not sufficiently long to translate into better asthma outcomes. 302 303 Chronic conditions require long-lasting interventions to promote health behavior changes, such as motivation for medication adherence, smoking cessation, and risk reduction 304 305 strategies (avoidance of triggers and pollutants). Clinical changes may have occurred outside 306 the timeframe of the observation period. There was an improvement in the use of controller 307 medications (which is a process indicator), we would therefore expect a decrease in asthma 308 exacerbation over a longer time span. Second, the study was underpowered. The initial 309 power calculation was based on the best available data, and suggested that 160 000 patients targeted by the program with a participation rate of 10% would give 80% power to detect a 310

311 5 % increase in the primary outcome among SA participants. Unfortunately, the number of 312 individual eligible to the program and the participation rate were smaller than anticipated. 313 The low uptake of the intervention may be due to early assessment (some people may have started to participate after the implementation period). It could also be due to suboptimal 314 315 targeting of patients diagnosed with asthma: the algorithm used to target the population (at 316 least two deliveries of R03 over the last 12 months) was probably not specific enough, 317 stressing the need for a more specific targeting of the SA program. Third, the population was 318 mainly of low severity asthma, with only 3.7% with LTD status for severe asthma, and 0.36% with an asthma-related hospitalization in 2014. Thus the room for improvement on severe 319 outcomes as hospitalization was very small. Hence, we performed a priori and post-hoc sub-320 321 group analysis, so that the captured population better matches the population of interest. 322 These analysis generated results congruent with the primary analysis, but relatively larger and significant positive effects were observed for some of the secondary treatment-related 323 and clinically relevant outcomes (including asthma exacerbations and sickleave days). 324 325 Fourth, the participation rate to the SA program was low at this early evaluation, inducing a 326 dilution effect. Fifth, we cannot exclude that the program lacked of a component primarily 327 targeting healthcare professionals (e.g., physician education and training). The use of written 328 personalized action-plan for self-management support may also have been missing. 329 According to the literature, even in countries that have been proactive about recommending asthma self-management, three quarters of asthmatic patients are not provided with 330 written action plans.<sup>27,28</sup> Finally, our findings are consistent with the literature indicating 331 332 overall small effects and no effect on ER visits. <sup>6,29</sup>

Major strengths of this study include the use of routinely collected health data and the large
number of geographical areas involved, allowing a very good external validity of the results;

335 the large sample size, enabling precise effect size estimates; and the relevance of outcomes assessed. In particular, effects on asthma exacerbations and days off work are typically 336 insufficiently reported in studies evaluating asthma management programs, according to the 337 Cochrane systematic review published recently by Peytremann-Bridevaux and colleagues. <sup>27</sup> 338 Keeping in line with their recommendations, we assessed process of care indicators (e.g., 339 340 MRA rate for controller medications, dispensation of controller medications) and healthcare 341 utilization indicators (e.g., routine GP visits, ER visits) to better interpret the outcomes 342 results at the patient-level.

However, some limitations should be considered when interpreting the results of this study. 343 344 First, the design of the evaluation was performed after the implementation perimeter was planned by the CNAM means that it was not possible to randomly assign patients to the 345 346 intervention and control groups nor to promote a more focused target population. We used, as recommended in such cases, <sup>30</sup> a controlled before-and-after quasi-experimental design 347 with matching on stratification variables and propensity score. Quasi-experimental studies 348 (where individuals are not randomly allocated)<sup>30</sup> include some attempt to limit or control 349 350 threats to internal validity but we cannot exclude the possibility of a residual confounding 351 bias Second, in healthcare databases, outcomes are usually addressed by use of proxies, which can induce measurement errors. However, we used proxies similar to those used in 352 353 other studies, and, by design, these measurement errors are not differential, thus can only 354 bias towards the null. Third, as stated above, the study was underpowered. The a posteriori 355 power (keeping the initial assumptions) in the light of observed numbers is of 52% to detect a 356 difference of 5% among the program participants and matched unexposed people (corresponding to 357 a difference of 0.4 % for the whole study population). Here we had a power of 80% to detect in the 358 program participants a difference of 7% (0.6% for the whole study population)

#### 359 CONCLUSION

In conclusion, SA program piloting phase was not associated with a significant effect at this early phase evaluation on the primary outcome, the ICS+LTRA/R03 ratio. It had a modest impact on some secondary outcomes, particularly on specific subgroups of patients more likely to be asthmatic, leaving open the possibility that suboptimal targeting of the population undermined the evaluation of the program effectiveness.

365 Our results can help the CNAM making informed decisions about whether and how to 366 continue to support this program, by improving the targeting of the population and 367 considering reformulation of the program followed by a subsequent evaluation.

#### 368 ACKNOWLEDGEMENTS

This study was commissioned and funded by the Caisse Nationale d'Assurance Maladie (CNAM), Paris, France. The CNAM did not have any role in the trial design, data analysis and interpretation, the writing of the manuscript and the decision to submit it for publication. However, they were in charge of data collection (as we used the French claims database and some data from the Sophia Asthme program run by the CNAM).

## 375 **REFERENCES**

- 1 Raherison C, Bourdin A, Bonniaud P, *et al.* Updated guidelines (2015) for management
  and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of
  the Société de Pneumologie de Langue Française (SPLF) (Full length text). *Rev Mal Respir*2016; **33**: 279–325.
- To T, Stanojevic S, Moores G, *et al.* Global asthma prevalence in adults: findings from the
   cross-sectional world health survey. *BMC Public Health* 2012; **12**: 204.
- 382 3 WHO | Asthma. WHO. http://www.who.int/mediacentre/factsheets/fs307/en/ (accessed
   383 Feb 28, 2018).
- 4 Demoly P, Paggiaro P, Plaza V, *et al.* Prevalence of asthma control among adults in France,
   Germany, Italy, Spain and the UK. *Eur Respir Rev Off J Eur Respir Soc* 2009; **18**: 105–12.
- 5 Fuhlbrigge A, Reed ML, Stempel DA, Ortega HO, Fanning K, Stanford RH. The status of asthma control in the U.S. adult population. *Allergy Asthma Proc* 2009; **30**: 529–33.
- Peytremann-Bridevaux I, Arditi C, Gex G, Bridevaux P-O, Burnand B. Chronic disease
   management programmes for adults with asthma. *Cochrane Database Syst Rev* 2015; :
   CD007988.
- 391 7 sophia, le service d'accompagnement de l'Assurance Maladie | ameli.fr.
- https://www.ameli.fr/assure/sante/assurance-maladie/sophia/service-sophia-assurance maladie (accessed Feb 28, 2018).
- Bateman ED, Hurd SS, Barnes PJ, *et al.* Global strategy for asthma management and
   prevention: GINA executive summary. *Eur Respir J* 2008; **31**: 143–78.
- 396 9 13 Including non-randomized studies. http://handbook-5-
- 397 1.cochrane.org/chapter\_13/13\_including\_non\_randomized\_studies.htm (accessed Feb398 28, 2018).
- 10 Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann
   Intern Med 1997; 127: 757–63.
- 401 11 Little RJ, Rubin DB. Causal effects in clinical and epidemiological studies via potential
   402 outcomes: concepts and analytical approaches. *Annu Rev Public Health* 2000; **21**: 121–45.
- 403 12 Linden A, Adams JL, Roberts N. Using Propensity Scores to Construct Comparable Control
  404 Groups for Disease Management Program Evaluation: *Dis Manag Health Outcomes* 2005;
  405 13: 107–15.
- 406 13TREND statement | CDC. https://www.cdc.gov/trendstatement/ (accessed April 17, 2017).
- 407 14Laforest L, Licaj I, Devouassoux G, Chatte G, Martin J, Ganse EV. Asthma drug ratios and
  408 exacerbations: claims data from universal health coverage systems. *Eur Respir J* 2014; **43**:
  409 1378–86.

- 15 Schatz M, Zeiger RS, Vollmer WM, *et al.* The controller-to-total asthma medication ratio is
   associated with patient-centered as well as utilization outcomes. *Chest* 2006; **130**: 43–50.
- 412 16 Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy
  413 administrative databases: a proposal for standard definitions and preferred measures.
  414 Ann Pharmacother 2006; 40: 1280–8.
- 415 17 Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data
   416 within French health insurance databases and implications for pharmacoepidemiological
- 417 studies. *Fundam Clin Pharmacol* 2016; **30**: 616–24.
- 418 18Tuppin P, Rudant J, Constantinou P, *et al.* Value of a national administrative database to
  419 guide public decisions: From the système national d'information interrégimes de
  420 l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in
- 421 France. *Rev Epidemiol Sante Publique* 2017; **65 Suppl 4**: S149–67.
- 422 19WHO | International Classification of Diseases. WHO.
- 423 http://www.who.int/classifications/icd/en/ (accessed Feb 28, 2018).
- 20 Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L. French health
  insurance databases: What interest for medical research? *Rev Med Interne* 2015; **36**: 411–
  7.
- 21 Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index
  and mortality in France over the period 1997 2001: variations with spatial scale, degree
  of urbanicity, age, gender and cause of death. *BMC Public Health* 2009; **9**: 33.
- 430 22 Statistiques | Insee.
- 431 https://www.insee.fr/fr/statistiques?debut=0&theme=69&geo=FRANCE-1 (accessed
- 432 March 1, 2018).
- 433 23 Résumé rapport 1820. IRDES. Institut de Recherche en Economie de la santé.
- 434 http://www.irdes.fr/EspaceRecherche/BiblioResumeEtSommaire/2011/Rapport1820.htm
  435 (accessed March 1, 2018).
- 436 24 Guignon N, Collet M, Gonzalez L. La santé des enfants en grande section de maternelle en
  437 2005-2006. Études et Résultats, DREES 2010, n° 737.
- 438 25 de Saint Pol Th. Les inégalités géographiques de santé chez les enfants de grande section
  439 de maternelle. BE H 2011, n°31.
- 26R: The R Project for Statistical Computing. https://www.r-project.org/ (accessed March 1, 2018).
- 27 Wiener-Ogilvie S, Pinnock H, Huby G, Sheikh A, Partridge MR, Gillies J. Do practices comply
  with key recommendations of the British Asthma Guideline? If not, why not? *Prim Care Respir J J Gen Pract Airw Group* 2007; **16**: 369–77.

- 28Sulaiman N, Aroni R, Thien F, *et al.* Written Asthma Action Plans (WAAPs) in Melbourne
   general practices: a sequential mixed methods study. *Prim Care Respir J J Gen Pract Airw*
- 447 *Group* 2011; **20**: 161–9, 1 p following 169.
- 29 Lemmens KMM, Nieboer AP, Huijsman R. A systematic review of integrated use of
   disease-management interventions in asthma and COPD. *Respir Med* 2009; **103**: 670–91.
- 450 30 anonymous. EPOC-specific resources for review authors | Cochrane Effective Practice and
- 451 Organisation of Care. http://epoc.cochrane.org/epoc-specific-resources-review-authors
  452 (accessed March 21, 2016).

## TABLES

 Table 1. Characteristics of the included subjects during the "before program" period, across groups: Sophia Asthme Program intervention (with program participants and non-participants) and matched unexposed groups.

Variables	Int	ervention (i.e. exposed) gr		Unexposed group	
	Total	Program participants	Program non- participants	P value	
No. of subjects	99,578	9,226	90,353		99,578
Demographics					
Age (years), mean (SD)	34·40 (7·25)	35·32 (7·18)	34·30 (7·25)	<0.0001	34·22 (7·45)
Female	60,076 (60·33%)	5,837 (63·27%)	54,240 (60·03%)	<0.0001	60,454 (60·71%)
CMU-C* recipient	19,366 (19·45%)	1,968 (21·33%)	17,398 (19·26%)	<0.0001	20,819 (20·91%)
Rey deprivation index (un the GP is professionally b	weighted) quintiles of ased	the municipality where		<0.0001	
1 <sup>st</sup> quintile	26 <i>,</i> 828 (26·94%)	2,369 (25.68%)	24,459 (27·07%)		24,474 (24·58%)
2 <sup>nd</sup> quintile	20,107 (20·19%)	1,847 (20·02%)	18,260 (20·21%)		20,102 (20·19%)
3 <sup>rd</sup> quintile	14,803 (14·87%)	1,310 (14·20%)	13,493 (14·93%)		14,633 (14·70%)
4 <sup>th</sup> quintile	14 <i>,</i> 963 (15·03%)	1,408 (15·26%)	13,556 (15·00%)		15,391 (15·46%)
5 <sup>th</sup> quintile	22,877 (22·97%)	2,292 (24·84%)	20,585 (22·78%)		24,978 (25·08%)
Geographic location of GP	10,223 (10·27%)	843 (9·14%)	9,380 (10·38%)	0.0002	10,951 (11·00%)
Long-term chronic disease status for severe asthma in 2014	3,706 (3·72%)	570 (6·18%)	3,136 (3·47%)	<0.0001	6,428 (6·46%)

(or before)					
Asthma-related hospitalization in 2014	355 (0·36%)	82 (0.89%)	273 (0·30%)	<0.0001	355 (0·36%)
No. of R03 medications					
No. of RO3 prescription dispensed during the "before program implementation" period, mean (SD)	4·46 (3·03)	4·87 (3·04)	4·41 (3·02)	<0.0001	6·10 (4·71)
No. of R03 prescriptions dispensed in 2012, mean (SD)	7.74 (6.08)	8·56 (5·94)	7.66 (6.08)	<0.0001	5·39 (5·18)

Data are no. (%) of patients, unless otherwise indicated.

\*CMU-C, complementary universal health coverage.

Table 2. Change in outcomes form the "before program implementation" period to the "after program implementation" period: a) forpatients in the intervention (i.e. exposed) and unexposed groups, b) for program participants and their matched unexposed

Table 2 a	Intervention (i.e. exposed) group (n=99,578)			Matche	d Unexposed (n=99,578)	d group			
	Per	iod	Absolute	Per	iod	Absolute	DiD	OR or slope <sup>a</sup>	P value
	"before program"	"after program"	Change	"before program"	"after program"	Change			
Process outcomes									
Indicators of asthma control									
ICS+LTRA/R03≥0.5	47,509 (47·71%)	42,588 (42·77%)	-4·9%	48,949 (49·16%)	44,067 (44·25%)	-4·9%	0.0%	1·00 (0·97;1·03)	0.8303
≥ 4 SABA	19,186 (19·27%)	17,887 (17·96%)	-1·3%	27,402 (27·52%)	25,468 (25·58%)	-1.9%	0.6%	1·02 (0·99;1·06)	0.1790
Controller medication									
At least one controller medication dispensed	61,713 (61·97%)	55,730 (55·97%)	-6%	67,383 (67·67%)	60,998 (61·26%)	-6·4%	0.4%	1·04 (1·01;1·07)	0∙0082
Sustained use of controller medication <sup>b</sup>	22,674 (22·77%)	21,288 (21·38%)	-1·4%	34,361 (34·51%)	31,614 (31·75%)	-2.8%	1.4%	1·08 (1·05;1·12)	<0.0001
Total no. of R03 dispensed, mean (SD)	5.99 (9.02)	5.67 (9.45)	-0.32	9.87 (14·72)	9.19 (14·79)	-0.68	0.36	0·36 (0·25- 0·47)	<0.0001
Adherence to controller asthma									
medications									
MRA>80%	7,069 (7·10%)	6,958 (6·99%)	-0.1%	14,407 (14·47%)	13,503 (13·56%)	-0.9%	0.8%	1·10 (1·04;1·16)	0∙0004

Healthcare utilization outcomes									
Urgent care visits									
At least one asthma-related hospitalization	355 (0·36%)	266 (0·27%)	-0.1%	355 (0·36%)	417 (0·42%)	0.1%	-0·2%	0·54 (0·42;0·69)	<0.0001
At least one ER visit for asthma	3,487 (3∙50%)	3,101 (3·11%)	-0·4%	4,723 (4·74%)	4,262 (4·28%)	-0.5%	0.1%	0·99 (0·92;1·06)	0.7084
At least one GP visit for asthma exacerbation <sup>c</sup>	32,731 (32·87%)	30,785 (30·92%)	-2%	31,452 (31·59%)	29,943 (30·07%)	-1.5%	-0·4%	0·98 (0·95;1·01)	0·1423
Routine visits									
At least one pulmonologist visit	11,355 (11·40%)	10,867 (10·91%)	-0.5%	11,785 (11·83%)	10,962 (11·01%)	-0.8%	0.3%	1·04 (1·00;1·08)	0.0774
At least one routine asthma GP visit <sup>d</sup>	59,017 (59·27%)	53,728 (53·96%)	-5·3%	63,153 (63·42%)	57,748 (57·99%)	-5·4%	0.1%	1·01 (0·99;1·04)	0.3642
At least one pulmonary function testing	12,075 (12·13%)	11,241 (11·29%)	-0.8%	12,346 (12·40%)	11,391 (11·44%)	-0.1%	0.1%	1·01 (0·97;1·06)	0.5625
Patient level outcomes									
At least one asthma exacerbation <sup>e</sup>	34,303 (34·45%)	32,247 (32·38%)	-2·1%	33,712 (33·85%)	31,930 (32·07%)	-1.8%	-0·3%	0.98 (0.96- 1.02)	0.3530
Work absenteeism									
No. of sickleave days related to asthma, mean number (SD), days	0.87 (9·35)	0.76 (8·43)	-0.11	0.90 (9.96)	0.88 (9·58)	-0.02	0.09	0·09 (- 0·20;0·03)	0·1360
At least one sickleave episode related to asthma	4,908 (4·93%)	4,613 (4·63%)	-0·3%	4,909 (4·93%)	4,768 (4·79%)	-0.1%	-0·2%	0·97(0·91;1·02)	0·2299
who had one or more days of sickleave days related to asthma, mean (SD) *	17,61 (38·46)	16,39 (35·73)	-1·22	18,32 (41·15)	18·43 (39·91)	0.11	-1·33	-	-

Table 2 b	Program participants (n=9,225)			Matched Unexposed group (n=9,225)					
	Per	iod	Absolute	Per	iod	Absolute	DiD	OR or slope <sup>a</sup>	P value
	"before program"	"after program"	Change	"before program"	"after program"	Change			
Process outcomes									
Indicators of asthma control									
ICS+LTRA/R03≥0.5	5 <i>,</i> 312 (57·58%)	5,073 (54·99%)	-2.6%	4,748 (51·47%)	4,393 (47·62%)	-3.8%	1.3%	1·06 (0·97;1·17)	0.1871
≥ 4 SABA	2,230 (24·17%)	2,186 (23·70%)	-0.5%	2,743 (29·73%)	2,563 (27·78%)	-2.0%	1.5%	1·10 (0·99;1·20)	0.0861
Controller medication									
At least one controller medication dispensed	6,945 (75∙28%)	6,518 (70·66%)	-4.6%	6,630 (71·87%)	6,046 (65∙54%)	-6·3%	1.7%	1·09 (0·98; 1·20)	0.1093
Sustained use of controller medication <sup>b</sup>	2,790 (30·24%)	2,799 (30·34%)	0·1%	3,611 (39·14%)	3,267 (35∙41%)	-3.7%	3.8%	1·29 (1·16;1·43)	<0.0001
Total no. of R03 dispensed, mean (SD)	7·78 (10·00)	7·84 (11·50)	0.06	10·80 (14·22)	10·10 (15·12)	-0.7	0.76	0·76 (0·36;1·16)	0.0002
Adherence to controller asthma									
medications MRA>80%	896 (9·71%)	947 (10·27%)	0.6%	1,518 (16·46%)	1,455 (15·77%)	-0.7%	1.2%	1·17 (1·01;1·36)	0∙0354
Healthcare utilization outcomes									
Urgent care visits									
At least one asthma-related hospitalization, mean (SD)	82 (0·89%)	47 (0·51%)	-0·4%	82 (0·89%)	58 (0·63%)	-0·3%	-0.1%	0·73 (0·40;1·35)	0.3182
At least one ER visit for asthma	513 (5·56%)	420 (4·55%)	-0.1%	507 (5·50%)	435 (4·72%)	-0.8%	-0·2%	0·95 (0·78;1·15)	0.5882

At least one GP visit for asthma exacerbation <sup>c</sup>	3 <i>,</i> 408 (36·94%)	3,087 (33·46%)	-3.5%	2,942 (31·89%)	2,828 (30·66%)	-1·2%	-2·2%	0·90 (0·82;0·99)	0.0229
Routine visits									
At least one pulmonologist visit	1,685 (18·27%)	2,067 (22·41%)	4·1%	1,181 (12·80%)	1,141 (12·37%)	-0·4%	4.6%	1·41 (1·25;1·59)	<0.0001
At least one routine asthma GP visit <sup>d</sup>	6,551 (71·01%)	6,062 (65·71%)	-5·3%	6,122 (66·36%)	5,626 (60·99%)	-5.4%	0.1%	0·99 (0·90;1·08)	0.7870
At least one pulmonary function testing	1,716 (18·60%)	2,091 (22·67%)	4·1%	1,233 (13·37%)	1,186 (12·86%)	-0.5%	4∙6%	1·40 (1·25;1·58)	<0.0001
Patient level outcomes									
At least one asthma exacerbation <sup>e</sup>	3643 (39·49%)	3267 (35∙41%)	-4.1%	3193 (34·61%)	3019 (32·73%)	-1.9%	-2·2%	0·90 (0.83;0·99)	0.0289
Work absenteeism									
No. of sickleave days related to asthma, mean number (SD), days	1·21 (10·73)	0.91 (8.78)	-0·30	1·07 (11·31)	1·10 (11·50)	0.03	-0.33	-0·33 (-0·59;- 0·07)	0.0119
At least one sickleave episode related to asthma	547 (5·93%)	479 (5·19%)	-0.7%	480 (5·20%)	497 (5·39%)	0.2%	-0·9%	0·83 (0·69;0·99)	0.0463
No. of days of sickleave days related to asthma among those who had one or more days of sickleave days related to asthma, mean (SD) *	20·39 (39·39)	17·52 (34·57)	-2.87	20·49 (45·41)	20·41 (45·42)	-0.08	-2.79	-	-

Data are no. (%) of patients, unless otherwise indicated. Values in bold indicate significant associations (p<0.05).

DiD, difference-in-differences (change in outcomes in exposed minus change in outcomes in the unexposed: if the DiD is positive, it means the increase in the variable is higher in the exposed vs unexposed); ER, emergency room; ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist; MRA, medication refill adherence; GP, general practitioner; SABA, short-acting  $\beta$ -agonist; LABA, long-acting  $\beta$ -agonist. <sup>a</sup> The following equation was used: Yi= $\beta$ 0 +  $\beta$ 1 INTERVENTION +  $\beta$ 2 PERIOD+  $\beta$ 3 (INTERVENTION X PERIOD) + ei where Yi is the value of the dependent variable for the i th patient, INTERVENTION is a dummy variable representing exposition to the program (INTERVENTION=1), PERIOD is a dummy variable (0="before program implementation" period and 1="after program implementation" period). The coefficient of the interaction term ( $\beta$  3) reflects the impact of the program).

<sup>b</sup> Defined as five or more units of ICS/LABA in a single inhaler and/or ICS as a single agent medicine, or 8 or more units of LTRA. This definition was issued from a scoping study provided by the CNAM (data not published).

<sup>c</sup> Defined as dispensation of oral or injectable corticosteroids within seven days of the GP visits.

<sup>d</sup> Defined as dispensation of R03 drugs within seven days of the GP visits.

<sup>e</sup> Defined as hospitalization, ER visits room or a visits to the general practitioner for exacerbation.

\* Models were not run as the patients were different.

Table 3. Estimation of SA impact for patients in the intervention and unexposed groups, sub-group analysis.

	Patients with R03 ≥ 3 in the year prior to program implementation			Patient	s with R03 ≥ 1	in 2012	Patients with asthma as defined by the CNAM algorithm		
	OR or slope	95% CI	P value	OR or slope	95% CI	P value	OR or slope	95% CI	P value
Process outcomes									
Indicators of asthma control									
ICS+LTRA/R03≥0.5	0.98	(0·95 ;1·01)	0.2309	0.98	(0.95;1.02)	0.3347	0.92	(0.88;0.97)	0.0014
≥ 4 SABA	1.04	(1.00;1.08)	0.0630	1.02	(0·99 ;1·06)	0.1880	0.94	(0·90;0·99)	0.0195
Controller medication									
At least one controller medication dispensed	1.08	(1.04;1.13)	0.0002	1.06	(1.03;1.10)	0.0006	0.94	(0·88 ; 1·01)	0.1193
Sustained use of controller medication <sup>a</sup>	1.08	(1·04 ;1·13)	<0.0001	1.07	(1.03;1.11)	0.0009	1.04	(0·99 ; 1·09)	0.1114
Total no. of R03 dispensed, mean (SD)	0.51	(0·35 ;0·67)	<0.0001	0.39	(0·25 ; 0·52)	<0.0001	0.34	(0·09; 0·60)	0.0080
Adherence to controller asthma									
medications									
MRA>80%	1.09	(1.04;1.15)	0.0007	1.07	(1.02;1.13)	0.0080	1.08	(1.02;1.14)	0.0139
Healthcare utilization outcomes									
Urgent care visits									
At least one asthma-related hospitalization	0.51	(0·39;0·67)	<0.0001	0.50	(0·39;0·65)	<0.0001	0.55	(0·40;0·74)	0.0001
At least one ER visit for asthma	0.97	(0.90;1.04)	0.3588	0.97	(0.91;1.05)	0.4610	0.93	(0.84;1.02)	0.1024

At least one GP visit for asthma exacerbation <sup>b</sup>	0.98	(0.95;1.01)	0.2220	0.98	(0.95;1.01)	0.1652	0.94	(0·90;0·98)	0·0071
Routine visits									
At least one pulmonologist visit	1.01	(0.96;1.06)	0.6157	1.01	(0.96;1.06)	0.7163	0.99	(0.93;1.05)	0.7958
At least one routine asthma GP visit $^{\rm c}$	1.01	(0.98;1.05)	0.4411	1.02	(0.99;1.06)	0.1430	0.89	(0.84;0.94)	<0.0001
At least one pulmonary function	0.00	(0.04.1.02)	0 45 40	0.00	(0.04.1.02)	0 4 4 0 0	0.06	(0.00.1.02)	0 1 7 0 0
testing	0.98	(0.94;1.03)	0.4248	0.98	(0.94;1.03)	0.4490	0.96	(0.90;1.02)	0.1100
Patient level outcomes									
At least one asthma exacerbation <sup>d</sup>	0.99	(0.96;1.02)	0.4722	0.99	(0.96;1.02)	0.3634	0.95	(0·91 ;0·99)	0.0310
Work absenteeism									
No. of sickleave days related to	-0.14	(-0·29;	0.0934	-0.14	(-0·28;-	0.0382	-0.29	(-0·53 ;-	0.0197
asthma, mean number (SD), days		0.02)			0.01)			0.05)	
At least one sickleave episode related to asthma	0.97	(0.90;1.04)	0.3403	0.96	(0.9; 1.03)	0.2625	0.92	(0·84 ;1·00)	0.0534

Data are no. (%) of patients, unless otherwise indicated. Values in bold indicate significant associations (p<0.05).

ER, emergency room; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LTRA, leukotriene receptor antagonist; SABA, short-acting β-agonists.

<sup>a</sup> Defined as five or more units of ICS/LABA in a single inhaler and/or ICS as a single agent medicine, or 8 or more units of LTRA. This definition was issued from a scoping study provided by the CNAM (data not published).

<sup>b</sup> Defined as hospitalization, ER visits room or a visits to the general practitioner for exacerbation

FUGURES

Figure 1 : Flow and selection of subjects records for inclusion into propensity analyses ;

